

Increased Capabilities for the Analysis of Hormones in **Drinking and Waste Water using SPE and LC/MS/MS**

Introduction

The presence of various hormones extraction and separation method, all in worldwide drinking water supplies while shortening the run time to less has been of public concern for some than 14 minutes. We expand the samtime. As the scientific community tries ple preparation technique to employ a to identify acceptable exposure limits, more versatile format for ease of use many new endogenous and synthetic in a variety of water matrices. By utihormones are being discovered. Com- lizing a SPE tube format and exploring pounds such as ethynylestradiol, the various particle sizes, differing water active ingredient in a commonly pre- sources can be scaled and processed scribed birth control medication, are more easily. In addition, the final exknown to cause detrimental effects tract concentration levels can be easily to both aquatic and human life. Many monitored and controlled to be more other compounds are currently being appropriate for a variety of different investigated. Due to this public risk, detectors, depending on the required there is a rapidly growing interest in sensitivity. monitoring these compounds. Within the United States, EPA Method 539 This study also offers an optimized was specifically developed to monitor LC/MS/MS method that explores ionthis growing problem.

This study builds on the foundation LC/MS/MS response. Because coned list of target analytes to include not stable under alkaline conditions, progesterone) and a more modern used to perform these analyses.

ization polarities and utilizes a high pH mobile phase in order to maximize of EPA 539 by providing an expand- ventional silica-based HPLC media is compounds of current interest (e.g. a core-shell organo-silica column was



Experimental Conditions

Sample Preparation

Pretreated Samples:

Per the EPA 539 method protocol, 1L water samples are dechlorinated, preserved, collected and stored All standards and QCs are freshly prepared in 50 % Methanol in water containing 20 ng/mL of working internal standards. We evaluated silica-based (Strata[®] C18-E) and polymer-based (Strata[™]-X) SPE sorbents. Strata C18-E provides recoveries of 91.1 - 103 % across all compounds (Table 3).

Optimized Solid Phase Extraction Method Cartridge: Strata C18-E, 1 g/20 mL

- Part No.: 8B-S001-JEG Condition: 10 mL Methano
- Equilibrate: 10 mL Water
- Load: Pretreated samples
- Wash: 10 mL 15 % Methanol in water Dry: 5 - 10 minutes under 10" Hg vacuum
- Elute: 2 x 6 mL Methanol
- Dry down: Evaporate completely under a stream of nitrogen @ 50 °C Reconstitute: Add 1.0 mL of 50 % Methanol in water containing 20 ng/mL of working internal standards.

SPE Accessories



LC/MS/MS Conditions



am	ple:
1.	Estriol
2.	Equilin
3.	Estrone ¹³ C ₃
4.	Estrone
5.	17β – Estradiol D ₅
6.	β – Estradiol
7.	17α - Ethynylestradiol
8.	Norethisterone
9.	Androstenedione
10.	Testosterone D ₃
11.	Testosterone
12.	Progesterone D _o
13.	Progesterone

faced with an AB Sciex API 4000 QTRAP, was for lowest detection level test only; all other experiments were done on Agilent 1260 L series with an AB Sciex API 4500 mass spectrometer.

Figure 2. Structure of the Organo-Silica **Kinetex EVO Particle**



Kinetex EVO: a patented organo-silica grafting process which incorporates uniform stabilizing ethane cross-linking to provide resistance to high pH attack while maintaining mechanical strength of the core-shell particle.

Stable to pH ~12

Table 1. MRM Transitions

Negative lons									
ID	Q1	Q3	RT (min)	Dwell	DP	EP	CE	CXP	
Beta-estradiol 1	271.1	145	6.34	75	-92	-10	-51	-14	
Beta-estradiol 2	271.1	183.3	6.34	75	-92	-10	-51	-15	
Estriol 1	287.1	145.2	4.21	75	-90	-10	-58	-17	
Estriol 2	287.1	171	4.21	75	-90	-10	-50	-17	
Equilin 1	267.1	143	5.80	75	-99	-12	-46	-20	
Equilin 2	267.1	223.1	5.80	75	-90	-12	-48	-12	
Estrone 1	269	145.1	6.14	75	-83	-10	-54	-23	
Estrone 2	269	143.2	6.14	75	-83	-10	-70	-23	
17α-Ethynylestradiol 1	295.3	145	6.46	75	-110	-10	-58	-17	
17α_Ethynylestradiol 2	295.3	183.3	6.46	75	-110	-10	-58	-17	
17 Beta-estradiol D ₅ 1	276.3	147	6.29	75	-90	-10	-55	-15	
18 Beta-estradiol D ₅ 2	276.3	187.1	6.29	75	-90	-10	-55	-15	
Estrone ¹³ C ₃ 1	272.2	148.1	6.13	75	-80	-10	-50	-20	
Estrone ¹³ C ₃ 2	272.2	162.1	6.13	75	-80	-10	-54	-20	
Positive lons									
ID	Q1	Q3	RT (min)	Dwell	DP	EP	CE	CXP	
Androstenedione 1	287.1	97.1	6.56	150	89	9	31	8	
Androstenedione 2	287.1	109	6.56	150	89	9	35	10	
Testosterone 1	289.1	97.2	7.20	150	81	9	37	8	
Testosterone 2	289.1	109.1	7.20	150	81	9	35	8	
Testosterone-D ₃ 1	292.2	97	7.19	150	91	9	33	6	
Testosterone-D ₃ 2	292.2	109	7.19	150	91	9	37	8	
Progesterone 1	315.4	109.1	9.67	150	86	9	35	10	
Progesterone 2	315.4	97.2	9.67	150	86	9	35	10	
Norethisterone 1	299.1	109	6.61	150	78	9	38	10	
Norethisterone 2	299.1	231	6.61	150	78	9	27	10	
Progesterone_D ₉ 1	324.4	100	9.61	150	87	9	30	10	
Progesterone_D ₉ 2	324.4	113	9.61	150	87	9	30	10	

Table 2. Mini Validation Results

ID	Final concentration (ng/L)	Accuracy%								
		Testosterone	Androstenedione	Progesterone	Norethisterone	17β-estradiol	Estriol	Equilin	Estrone	17α-Ethynylestradi
STD 1	0.0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STD 2	0.5	83.1	100	95.0	94.9	97.8	95.8	91.6	94.8	92.4
STD 3	1.0	105	100	94.8	100	98.2	92.6	94.5	94.8	89.0
STD 4	2.0	103	104	99.0	96.5	98.5	96.9	91.9	99.9	90.9
STD 5	10	104	107	102	100	99.8	94.0	95.7	94.8	102
STD 6	40	98.9	99.5	103	102	99.8	102	103	103	101
STD 7	50	100	98.8	97.2	98.2	100	100	99.2	98.8	99.8
QC L	2	104	105	97.2	101	101	103	90.8	102	93.0
QC M	20	103	103	93.5	93	103	99.7	96.9	99.6	102

STD 2 is Method Reported Limit (MRL)

Xianrong (Jenny) Wei, Sean Orlowicz, and Kristen Parnell Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501, USA

Table 3. Extracted Matrix Recovery



Figure 3. Representative of TIC Chromatogram







Figure 5. Representative of Negative Ion Chromatogram – 2.0 ng/L



Table 4. Method Limits and Linearity for Each Analyte Vegative Ion ID MRL (ng/L) LOD (ng/L) Linearity (R²) 0.05 Beta-estradio



Figure 6. Representative of Curve – Testosterone



Figure 7. Representative of Curve – β **-Estradiol**



Results and Discussion

On the foundation of EPA Method 539, allow an alkaline mobile phase to be a fast and reproducible SPE method used without compromising column for analyzing an expanded hormones lifetime, and increases compound senlist (Table 1) in drinking and waste wa- sitivity significantly. The lowest detecter using LC/MS/MS is developed. In tion limits on an AB Sciex 4000 QTRAP this study, we use Strata C18-E SPE can be reached at 0.05 ng/L for most in tube format to bring benefits such analytes (Table 4). as faster processing, increased sensitivity, consistency, and extraction efficiency (Tables 2 and 3).

The high pH mobile phase greatly im- tively analyze all target compounds in proves the ionization of some of the tar- one injection within 13.5 minutes (Figget compounds, resulting in improved **ures 3, 4 and 5)**, with mass spectrom-LC/MS/MS sensitivity. Because con- eter polarity switching. The represenunstable under alkaline conditions, the all positive and negative analytes are choice of analytical columns is very shown in **Figures 6** and **7**. limited. In this study, we selected a Phenomenex Kinetex 5 µm EVO C18 100 x 2.1 mm column, a core-shell organo-silica particle which incorporates uniform stabilizing ethane cross-linking and provides resistance to high pH attack, all while maintaining mechanical strength (Figure 2). These benefits

To improve sample analysis for high throughput in the lab, we have optimized LC/MS/MS procedures to effecventional silica-based HPLC media is tatives of linearity of analytes across

Conclusion

EPA Method 539 is a liquid chromatog- recovery and reproducibility. LC/MS/ raphy, electrospray ionization, tandem MS analysis time was significantly mass spectrometry method for the reduced from 55 minutes to 13.5 mindetermination of hormones in finished utes with a Kinetex 5 µ EVO C18 100 x drinking water. This work presents an 2.1 mm column, which delivers stabiloptimized method with an expanded ity under high pH mobile phase, while list of hormones that includes com- maintaining excellent linearity and pounds of current interest (e.g. pro- low detection levels. This method will gesterone and norethisterone) to suc- significantly increase laboratory processfully monitor a growing problem ductivity, efficiency, and throughput. in our scientific community. An SPE extraction method using Phenomenex Strata C18-E provides excellent

Acknowledgements

We would like to provide special thanks to Julissa Fernandez for sample preparation and all PhenoLogix team members for their technical assistance.

Trademarks

Strata and Kinetex are registered trademarks, and Strata-X is a trademark of Phenomenex. Agilent is a registered trademark of Agilent Technologies. Shimadzu is a registered trademark of Shimadzu Corporation. API 4000 and API 4500 are trademarks, and QTRAP is a registered trademarks of AB SCIEX Pte. Ltd. AB SCIEX is being used under license.

Kinetex EVO is patented by Phenomenex. U.S. Patent No. 7,563,367 and 8,658,038 and foreign counterparts. Strata-X is patented by Phenomenex. U.S. Patent No. 7,119,145

© 2015 Phenomenex, Inc. All rights reserved.